Effect of Atorvastatin on Plasma MicroRNA-143/145 Expression in Patients With Stable Angina Pectoris
10.3969/j.issn.1000-3614.2014.12.004
- VernacularTitle:阿托伐他汀对稳定性心绞痛患者血浆微小核糖核酸-143/145表达水平的影响
- Author:
Bei ZHAO
;
Lifeng LIU
;
Yingqi LIU
;
Li LIU
;
Jingtao ZHAO
;
Li ZHOU
;
Huihui XIA
;
Shouli WANG
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
MicroRNA;
Stable angina pectoris
- From:
Chinese Circulation Journal
2014;(12):972-975
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of atorvastatin on plasma microRNA-143/145 expression in patients with stable angina pectoris (SAP).
Methods: A total of 74 SAP patients taken atorvastatin at ifrst time were enrolled in this study, the patients were assigned into 2 groups by the dose of medication:Low dose group, the patients received atorvastatin 20 mg/day, n=36 and Moderate dose group, the patients received atorvastatin 40 mg/day, n=38. Plasma levels of LDL-C and microRNA-143/145 were examined before medication and at 1 month, 12 months after medication respectively. The patients were further divided into another 2 groups by plasma levels of LDL-C:Reach the standard group, plasma LDL-C<2.60 mmol/L and Not reach the standard group, plasma LDL-C≥2.60 mmol/L. Plasma levels of microRNA-143/145 were measured and compared between 2 groups.
Results: ① Compared with baseline condition, plasma levels of microRNA-143/145 were increased in both groups after medication, P<0.001 the levels in Moderate dose group were higher than those in Low dose group at both 1 month and 12 months of time points.②Plasma levels of LDL-C were decreased with medication in both groups, P<0.05. Micro RNA-143/145 expression was similar between Reach the standard group and Not reach the standard group, P>0.05.
Conclusion: Atorvastatin could up-regulate plasma microRNA-143/145 expression, which was not related to lipid-decreasing effect.
